Bristol Myers Squibb Company $BMY Shares Purchased by AIA Group Ltd

AIA Group Ltd lifted its position in shares of Bristol Myers Squibb Company (NYSE:BMY) by 20.1% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 189,914 shares of the biopharmaceutical company’s stock after acquiring an additional 31,842 shares during the quarter. AIA Group Ltd’s holdings in Bristol Myers Squibb were worth $11,518,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in BMY. waypoint wealth counsel purchased a new position in shares of Bristol Myers Squibb during the 4th quarter worth $1,194,000. Life Cycle Investment Partners Ltd acquired a new position in shares of Bristol Myers Squibb in the 4th quarter worth approximately $34,406,000. Axxcess Wealth Management LLC lifted its stake in Bristol Myers Squibb by 27.4% during the fourth quarter. Axxcess Wealth Management LLC now owns 98,665 shares of the biopharmaceutical company’s stock worth $5,322,000 after purchasing an additional 21,196 shares in the last quarter. Daytona Street Capital LLC acquired a new position in Bristol Myers Squibb during the 4th quarter worth about $1,362,000. Finally, Asset One Wealth Management LLC purchased a new position in shares of Bristol Myers Squibb in the fourth quarter valued at approximately $4,075,000. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on BMY shares. Guggenheim reiterated a “buy” rating and issued a $72.00 price objective on shares of Bristol Myers Squibb in a research note on Wednesday, April 8th. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $54.00 price objective on shares of Bristol Myers Squibb in a report on Monday, July 6th. Weiss Ratings lowered shares of Bristol Myers Squibb from a “hold (c+)” rating to a “hold (c)” rating in a research report on Thursday. Bank of America dropped their price target on Bristol Myers Squibb from $67.00 to $66.00 and set a “buy” rating on the stock in a research report on Friday, July 10th. Finally, Wall Street Zen raised shares of Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a research note on Saturday, June 27th. Eight investment analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $61.25.

Trending Headlines about Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: The FDA accepted Bristol Myers Squibb’s NDA for mezigdomide in relapsed/refractory multiple myeloma, a meaningful regulatory step that could strengthen the company’s oncology pipeline and future revenue prospects. Bristol Myers Squibb (BMY) Wins FDA Review For Mezigdomide In Multiple Myeloma
• Positive Sentiment: Unusual options activity showed traders buying a notably higher-than-average number of call options, suggesting some investors are positioning for additional upside in BMY.
• Positive Sentiment: Recent commentary highlighted Bristol Myers Squibb as a strong value stock, reinforcing the view that the shares may still look attractive on valuation grounds. Here’s Why Bristol Myers Squibb (BMY) is a Strong Value Stock
• Neutral Sentiment: Brokerage coverage continues to point to a “Hold” consensus, indicating analysts are not broadly turning more bullish or bearish on the stock. Bristol Myers Squibb Company (NYSE:BMY) Receives Consensus Rating of “Hold” from Brokerages
• Neutral Sentiment: Erste Group slightly lowered its FY2027 EPS estimate to $6.10 from $6.12, but the change is modest and still near consensus, so it is unlikely to be a major near-term driver by itself.
• Negative Sentiment: The small downward revision to longer-term earnings expectations may indicate some caution around Bristol Myers Squibb’s post-2026 growth trajectory, which could limit enthusiasm if investors focus on future profitability.

Bristol Myers Squibb Stock Performance

NYSE BMY opened at $60.71 on Friday. The company has a market capitalization of $123.97 billion, a P/E ratio of 17.05, a PEG ratio of 0.17 and a beta of 0.23. The company has a debt-to-equity ratio of 2.10, a current ratio of 1.42 and a quick ratio of 1.28. Bristol Myers Squibb Company has a 1-year low of $42.52 and a 1-year high of $62.89. The business has a 50 day moving average price of $57.02 and a 200 day moving average price of $57.78.

Bristol Myers Squibb (NYSE:BMY) last released its quarterly earnings data on Thursday, April 30th. The biopharmaceutical company reported $1.58 EPS for the quarter, topping the consensus estimate of $1.42 by $0.16. The business had revenue of $11.49 billion for the quarter, compared to analyst estimates of $10.93 billion. Bristol Myers Squibb had a net margin of 15.01% and a return on equity of 64.87%. The business’s revenue for the quarter was up 2.6% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.80 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Sell-side analysts expect that Bristol Myers Squibb Company will post 6.34 EPS for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, August 3rd. Stockholders of record on Thursday, July 2nd will be issued a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.2%. The ex-dividend date of this dividend is Thursday, July 2nd. Bristol Myers Squibb’s payout ratio is 70.79%.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.